These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24961288)

  • 21. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
    Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
    Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization.
    Pipa-Muñiz M; Sanmartino S; Mesa A; Álvarez-Navascués C; González-Diéguez ML; Cadahía V; Rodríguez JE; Vega F; Rodríguez M; Costilla-García SM; Varela M
    BMC Gastroenterol; 2020 Jun; 20(1):166. PubMed ID: 32487071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interventional treatment for unresectable hepatocellular carcinoma.
    Murata S; Mine T; Sugihara F; Yasui D; Yamaguchi H; Ueda T; Onozawa S; Kumita S
    World J Gastroenterol; 2014 Oct; 20(37):13453-65. PubMed ID: 25309076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.
    Yang B; Liang J; Qu Z; Yang F; Liao Z; Gou H
    PLoS One; 2020; 15(2):e0227475. PubMed ID: 32074102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.
    Zhang DZ; Wei XD; Wang XP
    World J Gastroenterol; 2015 Apr; 21(15):4635-43. PubMed ID: 25914473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
    Burrel M; Reig M; Forner A; Barrufet M; de Lope CR; Tremosini S; Ayuso C; Llovet JM; Real MI; Bruix J
    J Hepatol; 2012 Jun; 56(6):1330-5. PubMed ID: 22314428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Huo YR; Eslick GD
    JAMA Oncol; 2015 Sep; 1(6):756-65. PubMed ID: 26182200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
    Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
    Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DEB-TACE: a standard review.
    Melchiorre F; Patella F; Pescatori L; Pesapane F; Fumarola E; Biondetti P; Brambillasca P; Monaco C; Ierardi AM; Franceschelli G; Carrafiello G
    Future Oncol; 2018 Dec; 14(28):2969-2984. PubMed ID: 29987957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
    Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
    JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
    Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
    Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre.
    Eltawil KM; Berry R; Abdolell M; Molinari M
    HPB (Oxford); 2012 Mar; 14(3):162-70. PubMed ID: 22321034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Image-guided percutaneous locoregional therapies for hepatocellular carcinoma.
    Chevallier O; Zhao K; Marinelli B; Yarmohammadi H
    Chin Clin Oncol; 2023 Apr; 12(2):17. PubMed ID: 37081710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
    Lee EW; Khan S
    Clin Mol Hepatol; 2017 Dec; 23(4):265-272. PubMed ID: 29113030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.
    Moreno-Luna LE; Yang JD; Sanchez W; Paz-Fumagalli R; Harnois DM; Mettler TA; Gansen DN; de Groen PC; Lazaridis KN; Narayanan Menon KV; Larusso NF; Alberts SR; Gores GJ; Fleming CJ; Slettedahl SW; Harmsen WS; Therneau TM; Wiseman GA; Andrews JC; Roberts LR
    Cardiovasc Intervent Radiol; 2013 Jun; 36(3):714-23. PubMed ID: 23093355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
    Pawlik TM; Reyes DK; Cosgrove D; Kamel IR; Bhagat N; Geschwind JF
    J Clin Oncol; 2011 Oct; 29(30):3960-7. PubMed ID: 21911714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.